<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221116056524N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-24</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of dexmedetomidine infusion on the treatment of intraoperative shoulder pain</public_title>
      <acronym></acronym>
      <scientific_title>The effect of dexmedetomidine infusion on the treatment of intraoperative shoulder pain in diagnostic laparoscopic gynecological procedures under spinal anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66923</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: This study will be a prospective and randomized double-blind clinical trial, after obtaining the approval of the ethical committee and obtaining written informed consent from the patient, a number of 70 women aged 18-60 years with physical status ASA I, II (American Society of  Anesthesiologists), female  that candidates for diagnostic laparoscopic surgery  will be randomly divided into two groups.  By using the online software available at www.start.vbc.ca/nrolin/statssize/bz.htmf, patients will be entered into one of two groups of 35 people, Blinding description: In group A patients, before spinal anesthesia, intravenous bolus dexmedetomidine 1μg/kg was injected within ten minutes and then the infusion of dexmedetomidine 0.5 μg/kg/h was started, and in group B patients, infusion with the same volume and dose of 0.9 % sodium chloride serum was started as placebo by the anesthesiologist in charge of the procedure and will be continue until the patient is delivered to the PACU.All the operations will be performed by respected female surgeons who are at the same level of skill and experience. Vital signs of the patient including blood pressure, heart rate, SPO2, RR and ETCO2 upon entering the operating room, after dexmedetomidine bolus injection, before spinal anesthesia, after spinal anesthesia, before pneumoperitoneum, during pneumoperitoneum, after  Trendelenberg positioning, then it will be recorded every 5 minutes until the end of the procedure and after emptying the intra-abdominal gas and transferring the patient to the PACU.
 Also, the severity of shoulder or abdominal pain, based on VAS score and degree of sedation according to Ramsay sedation score (with the aim of maintaining a score of 2-3) will be recorded every 10 minutes until the end of surgery and in the PACU.Also, other side effects (respiratory depression, difficulty breathing, nausea and vomiting, chills, itching) will also be recorded and treated.
 Possible complications during surgery such as hypertension ,hypotension, bradycardia is recorded in all of the patients, and Also, the severity of shoulder or abdominal pain, based on VAS score and degree of sedation according to Ramsay sedation score (with the aim of maintaining a score of 2-3) will be recorded every 10 minutes until the end of surgery and in the PACU.Also, other complications (respiratory depression, difficulty breathing, nausea and vomiting, chills, itching) will also be recorded and treated.
 The duration of surgery and anesthesia and the time between the delivery of the patient in the PACU and obtaining full recovery parameters and the possibility of delivery to the ward will be recorded in both groups. Also, the satisfaction of the patient and the surgeon (in the form of non-satisfaction, moderate satisfaction, complete satisfaction) will also be recorded at the end of the surgery.</study_design>
      <phase>3</phase>
      <hc_freetext>The effect of dexmedetomidine infusion on the treatment of intraoperative shoulder pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:In 35 women, before entering the operating room and after initial monitoring and before spinal anesthesia, intravenous bolus dexmedetomidine 1μg/kg was injected within ten minutes and then the infusion of dexmedetomidine 0.5μg/kg/h was started and its effect on pain  The shoulder will be checked. Intervention 2: Control group: In 35 women, before spinal anesthesia, upon entering the operating room and after initial monitoring, one milliliter of sodium chloride 0.90% was injected intravenously as a placebo and its effect on shoulder pain will be investigated.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All potential data can be shared after making peoples unrecognizable.

When:
Starting 6 months after publication

To whom:
Documents will be available for people working in academic institutions and also people
working in businesses

Conditions:
There will be no specific limitations to the utilization of the data

Where to obtain:
Dr .Reyhaneh Abri, Department of Anesthesiology, Faculty of Medicine, Golgasht Street,
Tabriz East Azarbaijan Islamic Republic of Iran ,Phone+98 413 3341994, Fax+98 41 33341994 ,
re.abri@tbzmed.ac.ir

How to obtain:
Applicants will access the data from the present study by sending an email to the
responsible author for a maximum of one week

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reyhaneh abri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of anesthesiology, alzahra hospital, south artesh street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5174815811</zip>
        <telephone>+98 41 3553 9163</telephone>
        <email>reyhaneh.abri@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reyhaneh abri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of anesthesiology, alzahra hospital, south artesh street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5174815811</zip>
        <telephone>+98 41 3553 9163</telephone>
        <email>reyhaneh.abri@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Female with physical status ASA class I.II, candidate for diagnostic laparoscopic surgery for women in the age range of 18-60 years in Al-Zahra Hospital, Tabriz
Patient consent to enter the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Presence of any regional anesthesia contraindications, sensitivity to local anesthetics and dexmedetomidine
excessive obesity
Associated systemic diseases such as any history of cardiovascular, pulmonary, liver, kidney and etc.
Patient dissatisfaction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:In 35 women, before entering the operating room and after initial monitoring and before spinal anesthesia, intravenous bolus dexmedetomidine 1μg/kg was injected within ten minutes and then the infusion of dexmedetomidine 0.5μg/kg/h was started and its effect on pain  The shoulder will be checked.</i_keyword>
      <i_keyword>Control group: In 35 women, before spinal anesthesia, upon entering the operating room and after initial monitoring, one milliliter of sodium chloride 0.90% was injected intravenously as a placebo and its effect on shoulder pain will be investigated.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intraoperative shoulder pain in women's diagnostic laparoscopic surgeries. Timepoint: The severity of shoulder and abdominal pain, based on Visual Analogue Scale score and degree of sedation according to Ramsay sedation score, is recorded every 15 minutes until the patient's full recovery and delivery to the ward, and in case of Visual Analogue Scale scores higher than 3, the patient's pain will be treated with painkillers.  The dosage of additional drugs will also be recorded. Method of measurement: Based on Visual Analogue Scale score and Grade Sedation with Ramsay sedation score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>TABRIZ UNIVERSITY OF MEDICAL SCIENCES</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-11</approval_date>
        <contact_name>Ethics Committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Department of anesthesiology, alzahra hospital, south artesh street Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
